Nottingham Genomics Laboratory Service (NGLS)

The Nottingham Genomics Laboratory Service (NGLS) forms part of the integrated ‘East Genomic Laboratory’ (East GLH) service. NGLS is a UKAS accredited medical laboratory No. 8031. 

The East GLH is responsible for delivery of the genomic tests defined in the new National Genomic Test Directories.  The tests will be either delivered locally or via the East GLH laboratory hub at Addenbrooke’s Hospital, Cambridge. For current turnaround times please see table below.

By sending a sample, accompanied by a completed laboratory request form, the user enters into a service agreement for the Nottingham Genomics Laboratory Service (NGLS) to provide the service or test requested and agrees to the terms and conditions.

For further details of the tests delivered locally, select the links below to go to the pages for the Cytogenetics, Molecular Genetics and Molecular Diagnostics sections of the laboratory. 

Information about updates to genomic testing can be found on the East GLH website at East Genomics Updates. If you are interested in receiving regular updates about genomic testing in the East GLH you can sign up here — East Genomics Update Form.

From July 2025, UKAS accreditation for the service has been fully reinstated under ISO 15189:2022. As part of the reinstatement there was also a successful merger to include the whole Nottingham Genomics Laboratory Service under a single accreditation schedule (8031). Please see letter to users for further details.

East GLH and Nottingham University Hospitals NHS Trust comply with the Data Protection Act and the General Data Protection Regulation (GDPR) and take all possible care to maintain security and confidentiality of personal data.

When required by law or contractual obligation the laboratory will release confidential information. Any request to share patient information is managed and approved in accordance with NUH policies.  

Further information on how patient data is maintained can be found here:

Data Requests & Your Privacy | NUH

 

Page last updated 07/10/2025 Please note that if printed, this information is only valid on the day of printing

Current turnaround times

May 2025
 
 

Rare Disease Cytogenomics

Clinical Urgency

Example Tests

NHSE Target TAT (Days)

Percentage within Standard

Average TAT (Mean days)

Urgent - Rapid

Microarray / karyotypes for prenatal / urgent postnatal (e.g. neonatal referrals)

14

91%

11.5

Non-urgent - Standard

Standard paediatric or fetal loss microarray

42

46%

42.2

Non-urgent - Standard

Postnatal karyotyping (e.g. fertility or familial microarray follow-up)

42

22%

47.2

 

 

 

 

 

Rare Disease Molecular

Clinical Urgency

Example Tests

NHSE Target TAT (Days)

Percentage within Standard

Average TAT (Mean, Days)

Urgent – Ultra Rapid

QF-PCR for rapid trisomy detection

3

74%

2.5

Urgent – Ultra Rapid

PCR based prenatal diagnosis

3

0%

5

Urgent – Ultra Rapid

Targeted tests where the result is needed urgently

14

100%

6.5

Urgent – Rapid

Predictive testing

14

69%

10.5

Non-Urgent – Standard

Rare disease single gene screening, known familial variant testing & standard STR based analysis

42

20%

57.6

Non-Urgent – Standard

Rare disease small panel testing (<10 genes)

42

48%

45.8

Non-Urgent – Complex standard

WGS

84

19%

249.8

 

 

 

 

 

Haem-Onc Cytogenomics

Clinical Urgency

Example Tests

NHSE Target TAT (Days)

Percentage within Standard

Average TAT (Mean, Days)

Urgent – Ultra Rapid

Urgent haemato-oncology FISH PML::RARA

3

None received

0.3 (April)

Urgent – Ultra Rapid

Urgent haemato-oncology FISH BCR::ABL1

3

33%

4.7

Urgent - Rapid

Urgent haemato-oncology karyotyping/FISH

7

38%

5.4

Urgent - Rapid

Urgent haemato-oncology karyotyping/array/FISH

14

94%

8

Non-urgent - Standard

Standard haemato-oncology karyotyping/array/FISH

21

63%

17.4

 

 

 

 

 

Haem-Onc Molecular

Clinical Urgency

Example Tests

NHSE Target TAT (Days)

Percentage within Standard

Average TAT (Mean, days)

Urgent – Ultra Rapid

AML (FLT3, NPM1)

3

28%

5.4

Urgent - Rapid

AML NGS Panel

7

65%

7

MPN (JAK2, CALR)

21

74%

19.9

Urgent - Rapid

Chimerism

14

64%

15.4

Diagnostic BCR::ABL1

14

71%

13.4

BCR::ABL1 (Monitoring)

14

56%

15.6

 

 

 

 

 

Solid Cancer   

Clinical Urgency

Example Tests

NHSE Target TAT (Days)

Percentage within Standard

Average TAT (Mean, Days)

Urgent – Rapid

FISH for solid cancers

7

75%

6.8

Urgent – Rapid

BRAF

7

100%

3

Non-urgent Std

NGS-targeted DNA

14

74%

12.9

Non-urgent Std

NGS-targeted RNA

14

70%

13.8

Non-urgent Std

FISH for solid cancers

14

80%

13.7